Right. I think that LL's comparisons of the control arms of some of those trials was to demonstrate to her audience that when left to chemo/radiation, GBM patients all pretty much suffer a similar outcome. And because our control arm was messed up by the cross over, comparing the treatment arm to a large group of comparable patients should suffice. Plus, the control arm in the DCVax trial will not go to waste as those patients' very valuable contributions will be compared to similar comparable controls from other recurrent GBM trials... and may result in a statistically significant comparison here as well, which would (upon an approval) make DCVax-L available to recurrent GBM patients.
And just a side note: I don't know how many IDH mutated patients will be in this trial. But if there are a fair number, and we know now that IDH mutated are no longer considered GBM, but rather a lower grade glioma (like an astrocytoma), how might this translate to the use of DCVax-L in the lower grade gliomas?
Market Data 
Markets 
